Up-regulation of connexin 32 gene by 5-aza-2′-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling

Biochemical Pharmacology

Volumn 80, Issue 4, 2010, Pages 463-470

  Takano, Y ^a,b,c   Iwata, H ^b   Yano, Y ^d   Miyazawa, M ^a   Virgona, N ^a   Sato, H ^b   Ueno, K ^b   Yano, T ^a,e  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Hitachi   (Japan)

^d Ukyo ku   (Japan)

^e TOYO UNIVERSITY   (Japan)

Author keywords

5 Aza 2 deoxycytidine; Caki 1 cells; Connexin32; JNK; Renal cell carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CONNEXIN 32; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN C JUN; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; VINBLASTINE;

ARTICLE; CAKI 1 CELL; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONTROL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

AZACITIDINE; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CONNEXINS; DEOXYCYTIDINE; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; VINBLASTINE;

EID: 77953915322     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.05.016     Document Type: Article

References (32)

1. Jermal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Ather M.H., Masood N., Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J 2010, 7:1-9.
3. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
4. Bacoyiannis C., Dimopoulos M.A., Kalofonos H.P., Nicolaides C., Aravantinos G., Bafaloukos D., et al. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 2002, 63:130-138.
5. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
6. Naito S., Sakamoto N., Kotoh S., Goto K., Matsumoto T., Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993, 24:156-160.
7. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42:155-199.
8. Mesnil M., Yamasaki H. Cell-cell communication and growth control of normal and cancer cells: evidence and hypothesis. Mol Carcinog 1993, 7:14-17.
9. Mesnil M. Connexins and cancer. Biol Cell 2002, 94:493-500.
10. Duflot-Dancer A., Mesnil M., Yamasaki H. Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes. Oncogene 1997, 15:2151-2158.
11. Fujimoto E., Sato H., Shirai S., Nagashima Y., Fukumoto K., Hagiwara H., et al. Connexin 32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene 2005, 24:3684-3690.
12. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000, 60:3989-3999.
13. Sato H., Senba H., Virgona N., Fukumoto K., Ishida T., Hagiwara H., et al. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog 2007, 46:215-224.
14. Hirai A., Yano T., Nishikawa K., Suzuki K., Asano R., Satoh H., et al. Down-regulation of connexin 32 gene expression through DNA methylation in a human renal cell carcinoma cell. Am J Nephrol 2003, 23:172-177.
15. Yano T., Ito F., Kobayashi K., Yonezawa Y., Suzuki K., Asano R., et al. Hypermethylation of the CpG island of connexin 32, a candidate tumour suppressor gene in renal cell carcinomas from hemodialysis patients. Cancer Lett 2004, 208:137-142.
16. Hagiwara H., Sato H., Ohde Y., Takano Y., Seki T., Ariga T., et al. 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of connexin 32 gene. Br J Pharmacol 2008, 153:1373-1381.
17. Mack G.S. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006, 98:1443-1444.
18. Ji B.S., He L., Liu G.Q. Modulation of P-glycoprotein function by amlodipine derivatives in brain microvessel endothelial cells of rats. Acta Pharmacol Sin 2005, 26:166-170.
19. Yano T., Zissel G., Muller-Qernheim J., Shin S.J., Satoh H., Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 2002, 518:154-158.
20. Lin T., Trent J.M., Milliken D., Shimm D.S., Donaldson R., Hill A.B. Increased frequency of P-glycoprotein gene amplification in colchicine-resistant Rat-1 clones transformed by v-src. Cancer Genet Cytogenet 1997, 96:157-165.
21. Kang C.D., Ahn B.K., Jeong C.S., Kim K.W., Lee H.J., Yoo S.D., et al. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. Exp Cell Res 2000, 256:300-307.
22. Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001, 21:893-901.
23. Miao Z.H., Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003, 63:4527-4532.
24. Chu R., Upreti M., Ding W.X., Yin X.M., Chambers T.C. Regulation of Bax by c-Jun NH2-terminal kinase and Bcl-xL in vinblastine-induced apoptosis. Biochem Pharmacol 2009, 78:241-248.
25. Fujimoto E., Satoh H., Negishi E., Ueno K., Nagashima Y., Hagiwara K., et al. Negative growth control of renal cell carcinoma cell by connexin 32: possible involvement of Her-2. Mol Carcinog 2004, 40:135-142.
26. Omori Y., Krutovskikh V., Mironov N., Tsuda H., Yamasaki H. Cx32 gene mutation in a chemically induced rat liver tumor. Carcinogenesis 1996, 17:2077-2080.
27. Liu J.H., Yang M.H., Fan F.S., Yen C.C., Wang W.S., Chang Y.H., et al. Tamoxifen and colchicines-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Urology 2001, 57:650-654.
28. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62:3387-3394.
29. Gary M.J., Zhang J., Ellis L.M., Semenza G.L., Evans D.B., Watowich S.S., et al. HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110-3120.
30. Lu Y., Yu Q., Liu J.H., Zhang J., Wang H., Koul D., et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003, 278:40057-40066.
31. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001, 2:222-228.
32. Zhou J., Liu M., Aneja R., Chandra R., Lage H., Joshi H.C. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006, 66:445-452.